Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC

NCT04659369 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

21

Enrollment

INDUSTRY

Sponsor class

Stopped Difficult to recruit subjects

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: CMAB819
DRUG: Nivolumab

Sponsor

Taizhou Mabtech Pharmaceutical Co.,Ltd